Canadian Medical Association Journal · 2021 · 63 citations · 377 references
MedicineHematologyImmunologyAutoimmunityHemostasisImmunopathologyAnticoagulant TherapyAutoantigensPlatelet ActivationPlatelet DisordersPlatelet FunctionPlatelet PhysiologyBleeding Risk ReductionHeparin-induced ComplicationsImmune-mediated ThrombocytopeniaPositive Predictive ValueThrombotic Risk AssessmentThrombotic Risk ReductionThrombotic Risk Stratification
Heparin-induced thrombocytopenia is an uncommon condition mediated by anti-PF4 platelet-activating antibodies that typically begins 5–14 days after heparin initiation. Overall, greater risk is associated with unfractionated heparin than with low-molecular-weight heparin.[1][1] The platelet count
377
Mutation in blood coagulation factor V associated with resistance to activated protein C
Rogier M. Bertina, Bobby P. C. Koeleman, Ted Koster et al. · Nature · 1994 · 3.8K citations
Medicine, Genetics, Hematology +14
Hemostasis and Thrombosis: Basic Principles and Clinical Practice.
Annals of Internal Medicine · 1988 · 1.9K citations
Medicine, Hematology, Pathology +17
Jeffrey I. Weitz, Monika Hudoba, David Massel et al. · Journal of Clinical Investigation · 1990 · 1.1K citations · Full text
Medicine, Cardiology, Pharmacology +16
Temporal Aspects of Heparin-Induced Thrombocytopenia
Theodore E. Warkentin, J. G. Kelton · New England Journal of Medicine · 2001 · 975 citations · Full text
Medicine, Hematology, Pharmacology +11